Lytgobi (futibatinib)
An approved treatment for Cholangiocarcinoma.
The same compound appears under different names depending on the context. Here is how to identify Futibatinib wherever you encounter it, plus the key facts at a glance.
- Generic name
- Futibatinib
- Brand name
- Lytgobi
- Development code
- TAS-120
- Drug class
- Targeted small molecule (FGFR inhibitor)
- Manufacturer
- Taiho Oncology
- How it's taken
- Futibatinib is taken orally as a tablet at 20 mg once daily.
A daily oral tablet for adults with intrahepatic cholangiocarcinoma (bile duct cancer inside the liver) that has already been treated, cannot be removed by surgery or has spread, and has FGFR2 gene fusions or other rearrangements. It permanently shuts down the FGFR pathway that fuels growth in about 10-15% of these cancers.
We'll email you when Lytgobi's FDA label changes, when the FDA acts on it, and when new trials for Cholangiocarcinoma open. Unsubscribe anytime.
Where Futibatinib fits
Approved for previously treated intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements. Part of the growing precision oncology approach requiring molecular profiling of the tumor. It shares that setting with pemigatinib (approved 2020) and, since September 23, 2026, lirafugratinib (Lyrfigtu), and 2026 resistance studies suggest futibatinib can help some patients after lirafugratinib stops working.
How Futibatinib works
Futibatinib permanently binds to and blocks fibroblast growth factor receptors (FGFR), which are growth-promoting proteins. In cholangiocarcinoma with FGFR2 rearrangements, these receptors are constantly activated, driving cancer growth. Futibatinib's strong, permanent binding blocks this growth signal effectively.
Mechanism: Irreversible FGFR1-4 inhibitor
Side effects and safety
The most common side effects are nail changes (47%), musculoskeletal pain (43%), constipation (39%), and diarrhea (39%). Nearly all patients develop high phosphate levels in the blood. Other effects include fatigue, dry mouth, hair loss, and mouth sores. It can cause a serious eye problem called retinal pigment epithelial detachment, so eye exams including an OCT scan are needed before starting, every 2 months for the first 6 months, every 3 months after that, and right away for any vision changes. High phosphate levels can cause calcium deposits in soft tissues and blood vessels, so phosphate levels are checked and the dose may be paused, lowered or stopped. It can harm an unborn baby, so patients who could become pregnant, and men with partners who could, should use effective birth control during treatment and for 1 week after the last dose.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Futibatinib
Futibatinib is taken orally as a tablet at 20 mg once daily. It can be taken with or without food at about the same time each day. If side effects become problematic, the dose can be reduced to 16 mg or 12 mg.
Availability and cost
Only available as the brand-name product.
Targeted FGFR inhibitor for a molecularly defined cancer subset. The small eligible patient population (FGFR2 fusions/rearrangements occur in a minority of intrahepatic cholangiocarcinoma cases) drives orphan pricing.
Help paying for Lytgobi
Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.
- Copay help
$0 co-pay program for eligible commercially insured patients.
For: private insurance · source - Free medicine program
Patient assistance program provides free medication to eligible uninsured or underinsured patients.
For: no insurance, underinsured · source - Insurance and case manager help
Benefits review, specialty pharmacy coordination, optional nurse support, and referrals to foundations and Medicare Extra Help.
The official page does not say who qualifies. Ask the program. · source
Good to know: Full eligibility criteria at taihopatientsupport.com. Phone is 1-844-TAIHO-4U.
- From a charity · The Assistance FundBiliary Tract Cancer fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
The foundation says: “WAITLIST — Accepting Waitlist Patients. TAF is currently accepting requests to join the enrollment waitlist for this program. Waitlists a…”
Clinical trial results
In the Phase 2 TAS-120-101 trial, futibatinib achieved a 42% response rate in patients with FGFR2-rearranged cholangiocarcinoma, with a median response duration of 9.7 months. FDA granted accelerated approval on September 30, 2022.
Development history
Futibatinib (TAS-120) was developed by Taiho Pharmaceuticals/Otsuka as a next-generation FGFR inhibitor designed to overcome resistance mutations that develop with earlier FGFR inhibitors. It received accelerated FDA approval in 2022.
Explore Cholangiocarcinoma trials
Other Cholangiocarcinoma treatments
Common questions about Futibatinib
▸What is Futibatinib (Lytgobi)?
A daily oral tablet for adults with intrahepatic cholangiocarcinoma (bile duct cancer inside the liver) that has already been treated, cannot be removed by surgery or has spread, and has FGFR2 gene fusions or other rearrangements. It permanently shuts down the FGFR pathway that fuels growth in about 10-15% of these cancers.
▸How does Futibatinib work?
Futibatinib permanently binds to and blocks fibroblast growth factor receptors (FGFR), which are growth-promoting proteins. In cholangiocarcinoma with FGFR2 rearrangements, these receptors are constantly activated, driving cancer growth. Futibatinib's strong, permanent binding blocks this growth signal effectively.
▸What are the side effects of Futibatinib?
The most common side effects are nail changes (47%), musculoskeletal pain (43%), constipation (39%), and diarrhea (39%). Nearly all patients develop high phosphate levels in the blood. Other effects include fatigue, dry mouth, hair loss, and mouth sores. It can cause a serious eye problem called retinal pigment epithelial detachment, so eye exams including an OCT scan are needed before starting, every 2 months for the first 6 months, every 3 months after that, and right away for any vision changes. High phosphate levels can cause calcium deposits in soft tissues and blood vessels, so phosphate levels are checked and the dose may be paused, lowered or stopped. It can harm an unborn baby, so patients who could become pregnant, and men with partners who could, should use effective birth control during treatment and for 1 week after the last dose.
▸How is Futibatinib taken?
Futibatinib is taken orally as a tablet at 20 mg once daily. It can be taken with or without food at about the same time each day. If side effects become problematic, the dose can be reduced to 16 mg or 12 mg.
▸Is Futibatinib FDA approved?
Yes, Futibatinib (Lytgobi) is FDA approved (2022) for the treatment of Cholangiocarcinoma.
▸What makes futibatinib different from pemigatinib?
Futibatinib irreversibly (permanently) binds to FGFR receptors, while pemigatinib binds reversibly. Futibatinib also inhibits all four FGFR subtypes (1-4) versus pemigatinib's selectivity for FGFR1-3. The irreversible binding may help overcome certain resistance mutations.
▸What FGFR testing is needed?
Tumor genomic testing must confirm FGFR2 fusions or rearrangements before futibatinib can be prescribed. Only about 10-15% of cholangiocarcinoma patients carry these alterations, making molecular profiling essential.
▸What are the most common side effects?
Nail changes affect about 47% of patients, followed by musculoskeletal pain (43%), constipation (39%), diarrhea (39%), and high phosphate levels in nearly all patients. Most side effects are manageable with dose adjustments.
▸What response rates were seen in clinical trials?
In the TAS-120-101 trial, futibatinib achieved a 42% response rate in patients with FGFR2-rearranged cholangiocarcinoma, with a median response duration of 9.7 months. FDA granted accelerated approval in September 2022.
▸How is futibatinib taken?
Futibatinib is taken orally at 20 mg once daily, with or without food. If side effects become problematic, the dose can be reduced to 16 mg or 12 mg.
▸Who manufactures futibatinib?
Futibatinib (TAS-120) was developed by Taiho Pharmaceuticals/Otsuka as a next-generation FGFR inhibitor designed to overcome resistance that can develop with earlier FGFR inhibitors like pemigatinib.